Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline

Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p

BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the pric

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with

Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic a

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featurin

Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m

BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portugu

Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key st

STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharm

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris:

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris:

Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 resul

MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced th

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.

/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortli

Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority cl

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris:

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April

MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating I

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Par

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April

MARSEILLE, France--(BUSINESS WIRE)-- #Actionnaires--Innate Pharma to hold its annual general meeting

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) wit

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst co

BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward P

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in pat

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from